Help appealing denials for this RNA therapy for hemophilia prophylaxis.

Appeal Your Qfitlia Denial

Get access to this first antithrombin-lowering therapy for hemophilia.

Understanding Your Qfitlia (fitusiran) Denial

Qfitlia (fitusiran) is the first therapy that lowers antithrombin to prevent bleeding in patients with hemophilia A or B, with or without factor inhibitors. With just 6 injections per year using a convenient pen device, it offers a new approach to hemophilia prophylaxis. Insurance may require step therapy through factor products or emicizumab first.

Common Reasons for Denial

! Prior authorization required
! Must try factor replacement therapy first
! Must try emicizumab first (for hemophilia A)
! Step therapy requirement not met
! Inhibitor status not documented
! Ultra-high cost orphan drug

How We Help

We help you document your hemophilia diagnosis, bleeding history, current treatment regimen, and why Qfitlia offers benefits for your specific situation.

Start your Qfitlia appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Fitusiran is an siRNA that reduces antithrombin production, rebalancing hemostasis in hemophilia patients.

✓ Clinical trials demonstrated significant reduction in annualized bleeding rate with fitusiran prophylaxis.

✓ Every-two-month dosing significantly reduces treatment burden compared to more frequent factor infusions.

✓ Fitusiran works regardless of inhibitor status, providing an option for patients with this challenging complication.

Financial Assistance Directory

Curated copay foundations, manufacturer programs, and safety-net clinics that may help with the cost while you appeal.

For your condition

National Hemophilia Foundation (opens in a new tab)

Information on copay, insurance, and emergency assistance for hemophilia and related bleeding disorders.

General copay foundations & directories

NeedyMeds (opens in a new tab)

Searchable database of 5,000+ patient assistance, copay, and diagnosis-specific programs. Start here if you are not sure where to look.

Eligibility: No eligibility check - the directory itself is free. Individual programs have their own income and insurance criteria.

Patient Advocate Foundation Co-Pay Relief (opens in a new tab)

Direct copay assistance for insured patients with chronic, life-threatening, or rare conditions. Covers many disease funds.

Eligibility: Generally requires insurance coverage and income up to 400% of the federal poverty level (varies by fund).

Phone: 1-866-512-3861

HealthWell Foundation (opens in a new tab)

Independent charity providing copay, premium, and travel assistance grants across 70+ disease funds.

Eligibility: Must have insurance covering the prescribed treatment; income thresholds vary by fund. Funds open and close as donations allow.

The Assistance Fund (TAF) (opens in a new tab)

Copay, insurance premium, and travel assistance for patients with chronic and rare diseases.

Eligibility: Must have insurance and meet income limits (typically up to 500% FPL, fund-dependent).

Good Days (opens in a new tab)

Copay assistance and other support for chronic-disease patients.

Eligibility: Funds vary by disease and open/close based on availability. Usually requires insurance and income under ~500% FPL.

PAN Foundation (Patient Access Network) (opens in a new tab)

Disease-specific copay assistance funds for ~70 conditions. Funds open and close throughout the year - check the website or sign up for fund-open alerts.

Eligibility: Insurance required; income limits typically 400-500% of FPL depending on the fund.

NORD (National Organization for Rare Disorders) (opens in a new tab)

Patient assistance, copay, and travel programs for people living with rare diseases.

RxAssist Patient Assistance Program Center (opens in a new tab)

Comprehensive directory of manufacturer patient assistance programs. Search by medication to find the manufacturer's free-drug program if you are uninsured or under-insured.

Safety-net clinics & 340B

HRSA Find a Health Center (FQHC locator) (opens in a new tab)

Federally Qualified Health Centers (FQHCs) provide primary care on a sliding-fee scale and dispense many medications at 340B-discounted prices, regardless of insurance status. Often the cheapest path for uninsured or under-insured patients.

Hemophilia Treatment Center Directory (opens in a new tab)

CDC-recognized HTCs are 340B-covered entities that dispense clotting-factor products at discount, often via in-house pharmacies.

HRSA 340B Program (provider directory + program info) (opens in a new tab)

Background on the 340B Drug Pricing Program. Use to verify whether a particular clinic or hospital is a covered entity before assuming discounted pricing applies.

State Pharmaceutical Assistance Program (SPAP) directory (opens in a new tab)

State-run programs (mostly for seniors and people with disabilities) that supplement Medicare Part D and reduce prescription costs. Availability and benefits vary by state.

Medicaid eligibility & application (Healthcare.gov) (opens in a new tab)

If denied insurance is unaffordable, check Medicaid / CHIP eligibility - thresholds and pathways vary by state, and many expansion states cover adults up to 138% FPL.

Program eligibility, fund availability, and contact info change frequently. Verify with each organization before assuming a program is open.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

Sanofi HemAssist (Qfitlia)

Eligible patients may pay as little as $0 copay (up to $20,000/year). QuickStart provides up to 6 months free while awaiting coverage. Call 1-833-723-5463.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

National Bleeding Disorders Foundation

Patient advocacy organization for hemophilia and bleeding disorders since 1948.

Hemophilia Federation of America

National nonprofit serving the bleeding disorders community.

Frequently Asked Questions

Yes, Qfitlia is approved for hemophilia A or B with or without factor inhibitors. This is particularly important for patients with inhibitors who have limited treatment options.

Include your hemophilia type and severity, inhibitor status if applicable, bleeding history, current treatment regimen and burden, and any issues with current therapy (venous access, adherence challenges, breakthrough bleeds).

Ready to Fight Your Qfitlia (fitusiran) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Sanofi Genzyme / Alnylam. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.